Cartesian Therapeutics, Inc. (RNAC) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Cartesian Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -1.44x | -5.99x | -0.46x | 3.85x | -12.09x | -3.71x |
| P/B Ratio | -1.48x | -68.21x | -0.23x | 1.45x | 13.79x | -14.19x |
| P/S Ratio | 66.95x | 11.92x | 3.91x | 1.23x | 3.65x | 15.40x |
| Profitability | ||||||
| Gross Margin | 100.0% | 100.0% | 100.0% | 98.2% | 100.0% | 100.0% |
| Operating Margin | -3099.9% | -112.8% | -332.3% | 13.1% | -5.4% | -342.4% |
| Net Margin | -4658.6% | -199.0% | -844.9% | 31.9% | -30.2% | -415.0% |
| EBITDA Margin | -3099.9% | -195.3% | -903.8% | 36.0% | -6.1% | -395.2% |
| Liquidity | ||||||
| Current Ratio | 8.65x | 9.43x | 1.33x | 5.91x | 2.00x | 1.86x |
| Quick Ratio | 8.65x | 9.43x | 1.33x | 5.91x | 2.00x | 1.86x |
| Leverage | ||||||
| Debt/Equity | -0.10x | -2.06x | -0.02x | 0.40x | 1.57x | -1.96x |
YoY = year-over-year change. Source: FMP..